Cardiovascular Disease · Nutritional AssessmentTrial Updateclinicalmid-term

Nutritional Screening Study Aims to Link Nutritional Status to Surgical Outcomes

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 6:30:59 AM

Assessment confidence: 81% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

This study aims to establish a link between nutritional status and surgical outcomes in cardiovascular patients, which could reshape preoperative care practices. Pharma companies may need to adapt their strategies to incorporate nutritional assessments as part of their treatment protocols, potentially enhancing patient outcomes and satisfaction. Regulatory context from FDA (FDA AP — BUTORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (18 high-relevance).

Strategic Assessment

Pharma companies involved in cardiovascular treatments may need to consider nutritional support as part of their therapeutic strategies. The strongest clinical anchor is Nutritional Screening in Cardiovascular Disease (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular Disease · Nutritional Assessment, 8 regulatory and 2 competitive items passed relevance filtering for cardiovascular treatment companies.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study. This research could inform best practices in preoperative care, potentially impacting surgical protocols and patient management strategies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BUTORPHANOL TARTRATE (SUPPL) (FDA). Regulatory pathway relevance (nda). Changes in clinical guidelines based on this study could lead to new regulatory considerations for preoperative care in cardiovascular surgery, affecting compliance and approval processes.

Key Risks

Elevated medium regulatory exposure for cardiovascular treatment companies could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If nutritional support becomes a recognized component of cardiovascular treatment, companies may need to adjust their product offerings and marketing strategies, impacting market share and revenue streams.
Upside for cardiovascular treatment companies may improve if Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. (PubMed) delivers favorable follow-through.
Upside for cardiovascular treatment companies may improve if Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (ClinicalTrials.gov) delivers favorable follow-through.
Pharma companies involved in cardiovascular treatments may need to consider nutritional support as part of their therapeutic strategies.

What Would Change This Assessment

This becomes more urgent if Monitor results on the correlation between nutritional assessments and surgical outcomes, as well as potential changes in clinical guidelines.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Nutritional Screening in Cardiovascular Disease
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Cognitive-Based Balance Rehabilitation in Parkinson's Disease: Virtual Reality vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)

Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

cardiovascular treatment companies

Commercial impact

medium

If nutritional support becomes a recognized component of cardiovascular treatment, companies may need to adjust their product offerings and marketing strategies, impacting market share and revenue streams.

Regulatory impact

medium

Changes in clinical guidelines based on this study could lead to new regulatory considerations for preoperative care in cardiovascular surgery, affecting compliance and approval processes.

What to watch

Monitor results on the correlation between nutritional assessments and surgical outcomes, as well as potential changes in clinical guidelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.